EMA confirms risks of MS drug Zinbryta
The European Medicines Agency has concluded that the risks linked with use of Biogen and AbbVie’s multiple sclerosis drug Zinbryta outweigh its benefits.
Read More
Tag: Zinbryta
EMA recommends suspension, recall of Zinbryta
The European Medicines Agency is now recommending the immediate suspension and recall of Biogen’s multiple sclerosis therapy Zinbryta, just days after announcing a safety review.
Read More
Biogen, AbbVie pull MS drug from the market
European regulators have started an “urgent review” of Biogen and Abbvie’s multiple sclerosis therapy Zinbryta following a stream of cases of serious inflammatory brain disorders in patients taking the drug.
Read More
Scotland first UK nation to routinely offer HIV PrEP
Scotland will become the first UK nation to routinely offer HIV pre-exposure prophylaxis to all eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada alongside four other new therapies to be funded by the NHS.
Read More
NICE backs use of Biogen’s Zinbryta for MS
Eligible patients with multiple sclerosis should be able to get routine access to Biogen’s Zinbryta on the NHS in the next few months following a green light from cost regulators.
Read More
US regulators OK once-monthly MS shot
US patients with multiple sclerosis could soon gain access to a new treatment option after the US Food and Drug Administration approved Biogen and AbbVie’s once-monthly, self-administered subcutaneous injection Zinbryta.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
